Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **DNA methylation pathway** is an essential epigenetic mechanism involving the covalent addition of a methyl group to the 5-position of cytosine residues within CpG dinucleotides. This process is catalyzed by a family of enzymes known as **DNA methyltransferases**—primarily DNMT1, DNMT3A, and DNMT3B—which regulate both maintenance and de novo establishment of these marks during cell division and development. Methylated cytosines can alter chromatin structure directly or indirectly by recruiting proteins that recognize these modifications (“readers” such as MBD proteins), leading to transcriptional repression or activation depending on context. The patterning established by this pathway plays critical roles in regulating gene expression programs during embryogenesis, cellular differentiation, X-chromosome inactivation, genomic imprinting, aging processes, neurogenesis, immune function regulation—and is frequently dysregulated in human disease. Aberrant activity within the DNA methylation pathway contributes significantly to carcinogenesis through inappropriate silencing of tumor suppressor genes via promoter hypermethylation or genome-wide hypomethylation resulting in chromosomal instability. As such it has become both a **therapeutic target**—with drugs like azacitidine/decitabine approved for certain hematologic malignancies—and an important source for diagnostic/prognostic biomarkers across multiple disease areas including solid tumors and neurological disorders. However—as this entry refers not to a single molecular entity but rather an entire enzymatic/epigenetic process—it should be noted that “DNA methylation pathway” does not correspond precisely to one canonical druggable target but rather encompasses several related molecular targets within its network.[2][3][6][8]
– Inhibition of DNA methyltransferase enzymes to reduce or reverse abnormal gene silencing by demethylating tumor suppressor genes or other regulatory elements[5]
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA methylation pathway.